Noah L. Rosenberg - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
CMO
Signature
/s/ Jayson Rieger, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
25 Nov 2025
Net transactions value
+$10,000
Form type
4
Filing time
25 Nov 2025, 19:00:16 UTC
Previous filing
26 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rosenberg Noah L. CMO C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER /s/ Jayson Rieger, Attorney-in-Fact 25 Nov 2025 0001579649

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $10,000 +2,357 $4.24 2,357 25 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Series C Warrant (right to buy) Purchase +589 589 25 Nov 2025 Common Stock 589 $6.32 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 The reported securities are included within 2,357 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.